A Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of Fixed Dose Combination RHB-104 as Add-On Therapy to Interferon Beta-1a in Patients Treated for Relapsing Remitting Multiple Sclerosis

Trial Profile

A Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of Fixed Dose Combination RHB-104 as Add-On Therapy to Interferon Beta-1a in Patients Treated for Relapsing Remitting Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs Clarithromycin/clofazimine/rifabutin (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CEASE-MS
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 12 Dec 2016 Top-line final results published in the RedHill Biopharma media release.
    • 01 Aug 2016 Interim results published in a RedHill Biopharma media release.
    • 01 Aug 2016 According to a RedHill Biopharma media release, top-line results from this trial are expected in the fourth quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top